Synergistic antimicrobial effect of cefotaxime and minocycline on proinflammatory cytokine levels in a murine model of Vibrio vulnificus infection

Journal of Microbiology, Immunology and Infection

Volumn 40, Issue 2, 2007, Pages 123-133

  Chiang, Shyh Ren ^a   Tang, Hung Jen ^a   Chang, Ping Chin ^a   Cheng, Kuo Chen ^a   Ko, Wen Chien ^b   Chen, Chung Hua ^c   Chuang, Yin Ching ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c Ton Yen General Hospital   (Taiwan)

Author keywords

Antibacterial agents; Combination; Cytokines; Drug therapy; Vibrio vulnificus

Indexed keywords

CEFOTAXIME; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MINOCYCLINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DOSE RESPONSE; FEMALE; INTERMETHOD COMPARISON; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PERITONEAL FLUID; SKIN NECROSIS; VIBRIO VULNIFICUS; WOUND INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ASCITIC FLUID; CEFOTAXIME; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; MICE; MICE, INBRED BALB C; MINOCYCLINE; SURVIVAL ANALYSIS; VIBRIO INFECTIONS; VIBRIO VULNIFICUS;

EID: 34347256408     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Chuang YC, Young CD, Chen CW. Vibrio vulnificus infection. Scand J Infect Dis. 1989;21:721-6.
2. Hlady WG, Klontz KC. The epidemiology of Vibrio infections in Florida, 1981-1993. J Infect Dis. 1996;173:1176-83.
3. Bonner JR, Coker AS, Berryman CR, Pollock HM. Spectrum of Vibrio infections in a Gulf Coast community. Ann Intern Med. 1983;99:464-9.
4. Chuang YC, Yuan CY, Liu CY, Lan CK, Huang AH. Vibrio vulnificus infection in Taiwan: report of 28 cases and review of clinical manifestations and treatment. Clin Infect Dis. 1992; 15:271-6.
5. Morris JG Jr, Tenney J. Antibiotic therapy for Vibrio vulnificus infection. JAMA. 1985;253:1121-2.
6. Morris JG Jr, Black RE. Cholera and other vibrioses in the United States. N Engl J Med. 1985;312:343-50.
7. Jawetz E, Gunnison JB. An experimental basis of combined antibiotic action. J Am Med Assoc. 1952;150:693-5.
8. Chuang YC, Liu JW, Ko WC, Lin KY, Wu JJ, Huang KY. In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus. Antimicrob Agents Chemother. 1997;41: 2214-7.
9. Chuang YC, Ko WC, Wang ST, Liu JW, Kuo CF, Wu JJ, et al. Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother. 1998;42:1319-22.
10. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock. 2001;16:83-96.
11. Ingham E. Modulation of the proliferative response of murine thymocytes stimulated by IL-1, and enhancement of IL-1 beta secretion from mononuclear phagocytes by tetracyclines. J Antimicrob Chemother. 1990;26:61-70.
12. Koppenbrug M, Brinkman BM, de Rooij-Dijk HH, Miltenburg AM, Dana MR, Breedveld FC, et al. The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother. 1996;40:934-40.
13. Thong YH, Ferrante A. Effect of tetracycline treatment on immunological responses in mice. Clin Exp Immunol. 1980; 39:728-32.
14. Bessler H, Gurary N, Aloni D, Vishne TH, Sirota L. Effect of cefotaxime on cytokine production in newborns and adults in vitro. Biomed Pharmacother. 2000;54:410-4.
15. Van Vlem B, Vanholder R, De Paepe P, Vogelaers D, Ringoir S. Immunomodulating effects of antibiotics: literature review. Infection. 1996;24:275-91.
16. Shin SH, Shin DH, Ryu PY, Chung SS, Rhee JH. Proinflammatory cytokine profile in Vibrio vulnificus septicemic patients' sera. FEMS Immunol Med Microbiol. 2002;33:133-8.
17. Moellering RC Jr, Yao JD, Thornsberry C. Approximate concentrations of antimicrobial agents achieved in blood. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 7th ed. Washington, DC: American Society of Microbiology Press; 1999:1201-2.
18. de Groote MA, Martin MA, Densen P, Pfaller MA, Wenzel RP. Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs placebo. JAMA. 1989;262:249-51.
19. Debets JM, Kampmeijer R, van der Linden MP, Buurman WA, van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med. 1989;17:489-94.
20. Chorinchath BB, Kong LY, Mao L, McCallum RE. Age-associated differences in TNF-alpha and nitric oxide production in endotoxic mice. J Immunol. 1996;156:1525-30.
21. Leon LR, White AA, Kluger MJ. Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am J Physiol. 1998;275:R269-77.
22. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 1998; 319:397-400.
23. Nadel S, Newport MJ, Booy R, Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis. 1996; 174:878-80.
24. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev. 2002;15:95-110.
25. Shapira L, Soskolne WA, Houri Y, Barak V, Halabi A, Stabholz A. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect Immun. 1996;64: 825-8.
26. Matera G, Berlinghieri MC, Foti F, Barreca GS, Foca A. Effect of RO 23-9424, cefotaxime and fleroxacin on functions of human polymorphonuclear cells and cytokine production by human monocytes. J Antimicrob Chemother. 1996;38: 799-807.
27. Jackson JJ, Kropp H. beta-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis. 1992;165:1033-41.
28. Prins JM, Kuijper EJ, Mevissen ML, Speelman P, van Deventer SJ. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun. 1995;63:2236-42.
29. Simpson AJ, Opal SM, Angus BJ, Prins JM, Palardy JE, Parejo NA, et al. Differential antibiotic-induced endotoxin release in severe melioidosis. J Infect Dis. 2000;181:1014-9.
30. Evans ME, Pollack M. Effect of antibiotic class and concentration on the release of lipopolysaccharide from Escherichia coli. J Infect Dis. 1993;167:1336-43.
31. Bagby GA, Plessala KJ, Wilson LA, Thompson JJ, Nelson S. Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J Infect Dis. 1991;163:83-8.
32. Zanetti G, Heumann D, Gerain J, Kohler J, Abbet P, Barras C, et al. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide. J Immunol. 1992;148:1890-7.
33. Scheingraber S, Bauerfeind F, Bohme J, Dralle H. Limits of peritoneal cytokine measurements during abdominal lavage treatment for intraabdominal sepsis. Am J Surg. 2001;181: 301-8.
34. Marshall J, Sweeney D. Microbial infection and the septic response in critical surgical illness. Sepsis, not infection, determines outcome. Arch Surg. 1990;125:17-22.
35. Schein M, Wittmann DH, Holzheimer R, Condon RE. Hypothesis: compartmentalization of cytokines in intraabdominal infection. Surgery. 1996;119:694-700.
36. Holzheimer RG, Schein M, Wittmann DH. Inflammatory response in peritoneal exudate and plasma of patients undergoing planned relaparotomy for severe secondary peritonitis. Arch Surg. 1995;130:1314-9.